Anti-transforming growth factor beta as a treatment for laryngotracheal stenosis in a canine model

Laryngoscope. 2008 Mar;118(3):546-51. doi: 10.1097/MLG.0b013e31815daf6e.


Objectives/hypothesis: Laryngotracheal stenosis (LTS) represents a significant treatment dilemma faced by otolaryngologists. Recent topical use of Mitomycin C as an adjunctive treatment has proved helpful but does not completely prevent stenosis. Current literature suggests that transforming growth factor beta (TGFB) plays a significant role in the development of subglottic stenosis. We modified an existing canine model to test antitransforming growth factor beta (anti-TGFB) as a possible treatment for laryngotracheal stenosis.

Study design: Pilot study in a modified canine model.

Methods: Eight mixed-breed dogs underwent cautery injury to the subglottic region creating subsequent laryngotracheal stenosis. Four dogs were treated with saline injection into the injury site and four dogs were treated with a combination of intravenous (5 mg/kg on day 0 and 5 of the experiment) and local injection of anti-TGFB (50 micrograms).

Results: In the canine model of induced subglottic airway injury, a combination of intralesional and intravenous anti-TGFB results in a reduction in tracheal stenosis (P < .05) and an increase in survival time (P < .03) when compared to the saline control subjects.

Conclusions: Anti-TGFB appears to be a useful adjunct in the treatment of LTS. Further study regarding the optimal dosing, route of administration, and timing of delivery is needed to understand the role of anti-TGFB in the treatment for laryngotracheal stenosis.

MeSH terms

  • Animals
  • Antibodies / therapeutic use*
  • Disease Models, Animal
  • Dogs
  • Laryngostenosis / drug therapy*
  • Laryngostenosis / pathology
  • Tracheal Stenosis / drug therapy*
  • Tracheal Stenosis / pathology
  • Transforming Growth Factor beta / antagonists & inhibitors*
  • Transforming Growth Factor beta / immunology*


  • Antibodies
  • Transforming Growth Factor beta